In this issue:
- Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for NSCLC
- ESMO kidney cancer guidelines 2024
- Global epidemiology of kidney cancer
- Failure to obtain successful bowel cancer screening in New Zealand: high-risk groups
- Complete cancer prevalence in Europe in 2020
- International guidelines on anal cancer screening
- Ponsegromab for the treatment of cancer cachexia
- Optimal time from colorectal cancer surgery to adjuvant chemotherapy
- Response to neoadjuvant immunotherapy predicts relapse free survival in patients with HCC
- Predicting chemotherapy toxicity from genomic variants
- Evolving landscape of tissue-agonist therapies
- First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer
- Cancer drug approvals in New Zealand in 2024
- HRC funds NZ research into cancer clinical trial access
- FDA approves first engineered T-cell receptor therapy for cancer
- Smoking more than doubles the lung cancer mortality risk after radiation for breast cancer
- ASCO releases first guidelines on use of cannabis/cannabinoids for cancer patients
- Hundreds of potential druggable targets identified by pan-cancer proteogenomics
Please login below to download this issue (PDF)